New from PatientView: the 2025 global survey of how patient groups view pharma reputations
AI-translated from the Chinese original · editorially reviewed
This 2024/5 corporate reputation survey, conducted from December 2024 to March 2025, received responses from 2,546 patient groups across 100 countries—an all-time high. It reflects the growing voice and influence of patient communities in the healthcare ecosystem. Each year, PatientView surveys patient groups across different disease areas and regions, assessing not scientific data or profits, but how well companies build patient trust and partnerships.
Familiarity and trust: not the same thing
The report focuses on two key metrics: familiarity and partnerships. In theory, the two should rise together, but the data reveals a more complex picture.
Take Pfizer: it not only topped the familiarity rankings (1,664 mentions) but was also the company patient groups partnered with most often (932 mentions). Roche and Novartis showed the same dual strength, proving that companies that prioritize patient engagement gain not just recognition but trust.
AbbVie and Amgen, by contrast, enjoy high familiarity (1,012 and 790 mentions respectively), but their reported partnerships with patient groups did not measure up.
Small companies, big trust: niche strategies that work
Some smaller companies, or those focused on specific disease areas, performed impressively—Vertex, UCB, and Servier, for example, ranked lower in familiarity but achieved relatively high partnership ratios.
This shows that patient communities value genuine engagement over brand scale: even with limited resources, companies that invest in building authentic long-term relationships can earn loyalty.
How should pharmaceutical companies respond?
The report does more than expose problems—it points the way forward:
- Invest in genuine partnerships, not just marketing campaigns
- Truly listen to patient voices during development and launch
- Advance participation programs that include marginalized and rare disease patients
- Make patient trust a key performance indicator (KPI)
Conclusion
In 2024, a pharma company's reputation is earned not by who speaks the loudest, but by who listens the hardest. Trust and familiarity are no longer givens—they must be built through ongoing dialogue, collaboration, and action.
The pharmaceutical companies that succeed in healthcare going forward must transform from product suppliers into true patient partners. As the report makes clear: patients are watching, and waiting for your response.